Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shigella flexneri 2a whole cell vaccine + double mutant E. coli heat labile toxin
- Development stage
- Unknown
- Lead developer
- PATH
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
This is an oral combination vaccine candidate composed of a formalin-inactivated whole-cell *Shigella flexneri* 2a (Sf2aWC) and the double mutant *Escherichia coli* heat-labile toxin (dmLT; LT R192G/L211A) as a mucosal adjuvant. The primary indication is prevention of shigellosis caused by *Shigella flexneri* 2a, a major cause of severe diarrhea worldwide. The inactivated bacterial component induces immune responses against the lipopolysaccharide (LPS) and other antigens of *S. flexneri* 2a, while the dmLT adjuvant enhances both systemic and mucosal immunity by promoting IL-17A production from CD4+ T cells via antigen-presenting cells and cytokines such as IL-1β and IL-23[3][6][8]. Clinical studies have shown that this combination is safe, well-tolerated, immunogenic in adults, and capable of inducing robust anti-LPS antibody responses[3][5]. The addition of dmLT aims to further boost mucosal immune responses for improved protection.
- Other names
- Shigella flexneri 2a inactivated whole cell vaccine + double mutant Escherichia coli heat labile toxinSf2aWC + dmLTformalin-inactivated Shigella flexneri 2a whole cell vaccine with dmLT adjuvant
02
Targets
GM1 (GM1 ganglioside)
Beyond the preview
Go deeper on Shigella flexneri 2a whole cell vaccine + double mutant E. coli heat labile toxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shigella flexneri 2a whole cell vaccine + double mutant E. coli heat labile toxin.